Because serum tumor necrosis factor (TNF) is high in patients with Kawasaki disease (KD), infliximab, an anti-TNF agent, has been proposed as a potential treatment for refractory KD, but few randomized trials have been conducted to demonstrate the efficacy and safety of using infliximab in this setting.
Kawasaki disease (KD), an acute febrile disorder that primarily affects children aged 5 years or younger and can cause coronary artery abnormalities and acquired heart disease in children. Suppressing acute inflammation within 10 days of the disease’s onset is critical to preventing coronary artery lesions (CAL) in these patients.
While intravenous immunoglobulin (IVIG) is the initial therapy for KD, and typically leads to rapid defervescence (and therefore lower incidence of CALs), approximately 20% of patients do not respond adequately to IVIG. Often, IVIG-refractory KD is treated with an additional dose of IVIG, though half of refractory patients may not respond to the added dose.
Because serum tumor necrosis factor (TNF) is high in patients with KD, infliximab, an anti-TNF agent, has been proposed as a potential treatment for IVIG-refractory KD, but few randomized trials have been conducted to demonstrate the efficacy and safety of using infliximab in this setting.
Results of a small study of infliximab versus an additional dose of IVIG for treatment-refractory patients with KD, recently published in Scientific Reports, showed that infliximab improved the defervescence rate within 48 hours compared to treatment with IVIG, and that infliximab was well tolerated.
The study began on May 2012 and ended in September 2014. Because only a small group of patients met eligibility criteria, the recruitment target was not reached. In total, 31 patients were enrolled and randomized to receive either infliximab in a single intravenous dose of 5 mg/kg (n = 16) or intravenous polyethylene glycol-treated human immunoglobulin (VGIH) at a dose of 2 mg/kg (n = 15). The study’s primary outcome was the defervescence rate within 48 hours after treatment, and safety was evaluated through day 56.
The researchers found that:
The study’s authors say that, as prevention of CALs is among the most important goals of treating KD, and as anti-TNF therapy directly improves endothelial cell function and reduces inflammation, treating KD with infliximab may contribute to preventing development of coronary artery abnormalities. Larger and longer studies may help to confirm these trial results and provide longer-term outcomes with infliximab.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Pipelines and Preparation: How the US Can Prepare for More RA Biosimilars
April 16th 2023What can practices do to prepare for all the biosimilars to treat rheumatoid arthritis (RA) coming down the pipeline? And how can they ensure that the lower-than-anticipated adoption rates for infliximab biosimilars are not repeated? Robert Zutaut, RPh, from McKesson Provider Solutions, tackles all this and more on this episode of Not So Different.
Physician and Patient Perspectives After Starting or Switching to Amgevita in IBD
March 23rd 2024A real-world study surveying physicians and patients on adalimumab biosimilar ABP 501 (Amgevita) in inflammatory bowel disease (IBD) found both patients initiating ABP 501 and those who had switched from the reference product had higher satisfaction levels.